Amicus Therapeutics Inc
NASDAQ:FOLD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
US |
Multiples-Based Value
The Multiples-Based Value of one
FOLD
stock under the Base Case scenario is
10.958
USD.
Compared to the current market price of 14.415 USD,
Amicus Therapeutics Inc
is
Overvalued by 24%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
FOLD Competitors Multiples
Amicus Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
4.5B USD | 7.1 | -165.3 | 109.2 | 132.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.2B USD | 6.1 | 89.4 | 14.8 | 20.6 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.4B USD | 6.2 | -96.2 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.2 | 24.6 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.9B USD | 5.8 | 19.9 | 12.5 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 9.4 | 28.7 | 21.5 | 22.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.6B AUD | 3.2 | 34.9 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |